Texas Patent of the Month – February 2024

Trained Therapeutix Discovery, Inc is leveraging trained immunity and modern nanobiologic therapeutics to treat even the most detrimental of diseases. Trained immunity involves reprogramming of the innate immune cells at the metabolic level. By leveraging immune memory, the company hijacks the body’s natural mechanisms to engage the immune system with nanobiologics. 

Recently, the company has been granted a patent for compounds used in their trained immunity platform. The formula is designed with a unique structure with multiple variable groups allowing for precise customization. 

At its core, the invention taps into the innate immune system, specifically targeting the NOD2 receptor. Trained immunity, a recently explored facet of the immune system, involves the reprogramming of innate immune cells for enhanced functionality. Trained Therapeutix Discovery’s compound engages pattern recognition receptors (PRRs) like NOD2 to trigger and modulate trained immunity effectively.

The compound’s versatility is evident in its molecular architecture. R1, R2, R3, and other substituents can be tailored to achieve optimal therapeutic effects. This flexibility ensures the customization of the compound for different applications, making it a promising candidate for treating atherosclerosis, diabetes, and cancer.

The invention further extends to nanobiologic compositions, incorporating the compound into high-density lipoprotein (HDL)-derived nanoparticles. These nanoparticles, enriched with phospholipids and cholesterol, create an ideal environment for the compound’s delivery, ensuring its bioavailability to target myeloid cells and their progenitors.

In preclinical studies, Trained Therapeutix Discovery’s compound demonstrated its potential as a therapeutic agent, regulating trained immunity without the adverse effects associated with existing immunotherapies. The compound’s nanobiologic formulations pave the way for innovative treatment modalities, offering a new frontier in the field of immunotherapy.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts